ES2721152T3 - Método para comprobar la autocuración por el sistema inmunológico de un sujeto infectado con virus del papiloma humano - Google Patents
Método para comprobar la autocuración por el sistema inmunológico de un sujeto infectado con virus del papiloma humano Download PDFInfo
- Publication number
- ES2721152T3 ES2721152T3 ES12772206T ES12772206T ES2721152T3 ES 2721152 T3 ES2721152 T3 ES 2721152T3 ES 12772206 T ES12772206 T ES 12772206T ES 12772206 T ES12772206 T ES 12772206T ES 2721152 T3 ES2721152 T3 ES 2721152T3
- Authority
- ES
- Spain
- Prior art keywords
- hpv
- sample
- body fluid
- volunteer
- fluid sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/035—Herpes simplex virus I or II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Procedimiento para predecir la formación de carcinomas originados por virus del papiloma humano (VPH) en un voluntario infectado por VPH, que comprende las siguientes etapas: 1) extracción de al menos dos muestras que contienen células del voluntario, en donde una de las al menos dos muestras es una muestra de mucosa (muestra de la mucosa) y otra de las al menos dos muestras es una muestra de líquido corporal (muestra de líquido corporal); 2) determinación de si en la muestra de la mucosa los VPH contienen al menos una molécula de estímulo que estimula el sistema inmunológico del voluntario al reconocer mediante un anticuerpo un cambio morfológico y/o un cambio biomolecular de al menos una de las células de la muestra de mucosa como una alteración inducida por el VPH, en la que están involucrados los VPH con la molécula de estímulo, en donde la molécula de estímulo en consideración es la proteína L1 de la cápside de VPH de tipo 16 (VPH16) y los anticuerpos son específicos contra la 15 molécula de estímulo; 3) determinación de si la muestra de fluido corporal contiene anticuerpos endógenos contra el VPH con la molécula de estímulo mezclando la muestra de fluido corporal con un reactivo que consiste esencialmente en una cantidad predeterminada de líquido fisiológicamente activo y una cantidad predeterminada de al menos un antígeno, y luego 20 la mezcla se somete a un análisis que utiliza un cambio mensurable y/o perceptible por el usuario, en donde el antígeno es reactivo en referencia a los anticuerpos contenidos en la muestra de fluido corporal que son específicos contra la molécula de estímulo de VPH16 (anticuerpos específicos de VPH16L1); 4) evaluación en el sentido de que, cuando se detecta la molécula de estímulo en la etapa (2) y se detecta el anticuerpo endógeno en la etapa (3), se predice que la formación de carcinomas, causados por los VPH considerados, se evita por el sistema inmunológico del voluntario con muy alta probabilidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011053741A DE102011053741A1 (de) | 2011-09-19 | 2011-09-19 | Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen |
PCT/DE2012/100287 WO2013041087A1 (de) | 2011-09-19 | 2012-09-19 | Verfahren zum überprüfen der selbstheilung durch das immunsystem eines mit humanen papillomviren infizierten probanden |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721152T3 true ES2721152T3 (es) | 2019-07-29 |
Family
ID=47017993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12772206T Active ES2721152T3 (es) | 2011-09-19 | 2012-09-19 | Método para comprobar la autocuración por el sistema inmunológico de un sujeto infectado con virus del papiloma humano |
Country Status (7)
Country | Link |
---|---|
US (1) | US20140356861A1 (es) |
EP (1) | EP2758785B1 (es) |
CN (1) | CN104115011A (es) |
DE (2) | DE102011053741A1 (es) |
ES (1) | ES2721152T3 (es) |
PL (1) | PL2758785T3 (es) |
WO (1) | WO2013041087A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102016124171A1 (de) * | 2016-12-13 | 2018-06-14 | Abviris Deutschland Gmbh | Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8803870D0 (sv) * | 1988-10-28 | 1988-10-28 | Medscand Ab | Method for detection of human papillomavirus (hpv) for diagnostic purposes |
EP1271151A1 (en) * | 2001-06-20 | 2003-01-02 | Virofem Diagnostika GmbH | Assay and process for the detection of HPV antibodies |
US7972776B2 (en) * | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
US7838215B2 (en) * | 2007-09-25 | 2010-11-23 | Canvir, Inc. | Advanced cervical cell screening methods |
DE102010061028A1 (de) | 2010-12-03 | 2012-06-06 | Ralf Hilfrich | Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests |
-
2011
- 2011-09-19 DE DE102011053741A patent/DE102011053741A1/de not_active Withdrawn
-
2012
- 2012-09-19 PL PL12772206T patent/PL2758785T3/pl unknown
- 2012-09-19 US US14/345,411 patent/US20140356861A1/en not_active Abandoned
- 2012-09-19 CN CN201280056738.9A patent/CN104115011A/zh active Pending
- 2012-09-19 WO PCT/DE2012/100287 patent/WO2013041087A1/de active Application Filing
- 2012-09-19 ES ES12772206T patent/ES2721152T3/es active Active
- 2012-09-19 DE DE112012003896.7T patent/DE112012003896A5/de not_active Withdrawn
- 2012-09-19 EP EP12772206.4A patent/EP2758785B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
US20140356861A1 (en) | 2014-12-04 |
PL2758785T3 (pl) | 2019-10-31 |
WO2013041087A1 (de) | 2013-03-28 |
CN104115011A (zh) | 2014-10-22 |
DE112012003896A5 (de) | 2014-05-28 |
EP2758785B1 (de) | 2019-01-23 |
DE102011053741A1 (de) | 2013-03-21 |
EP2758785A1 (de) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Doorbar | Latent papillomavirus infections and their regulation | |
Reinholz et al. | HPV16 activates the AIM2 inflammasome in keratinocytes | |
Attia et al. | COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review | |
Christensen | HPV disease transmission protection and control | |
MX354822B (es) | Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. | |
TR201908199T4 (tr) | HPV'ye karşı aşılar. | |
CL2013002907A1 (es) | Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; y uso para reducir los niveles de proteina viral en una celula de un animal (div.sol.n°822-12). | |
Faust et al. | Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types | |
Brendle et al. | Pathogenesis of infection by human papillomavirus | |
JP2014533372A5 (es) | ||
Alfaro-Núñez et al. | Validation of a sensitive PCR assay for the detection of Chelonid fibropapilloma-associated herpesvirus in latent turtle infections | |
Giuliani et al. | Human papillomavirus oral infection: review of Methodological aspects and Epidemiology | |
Hampson et al. | Potential effects of human papillomavirus type substitution, superinfection exclusion and latency on the efficacy of the current L1 prophylactic vaccines | |
Flemming | Cross reactive T cells hold up against Omicron | |
ES2721152T3 (es) | Método para comprobar la autocuración por el sistema inmunológico de un sujeto infectado con virus del papiloma humano | |
McBride | Norovirus dose-response in sewage-related QMRA: the importance of virus aggregation | |
Chen et al. | The role of the globular heads of the C1q receptor in HPV-16 E2-induced human cervical squamous carcinoma cell apoptosis via a mitochondria-dependent pathway | |
Schiffman et al. | The use of human papillomavirus seroepidemiology to inform vaccine policy | |
Passmore et al. | Host immune responses associated with clearance or persistence of human papillomavirus infections | |
WO2014126487A3 (en) | Diagnosis and detection of dengue virus infection using chicken egg antibodies | |
Tønnessen et al. | Experimental inoculation of chickens with gull-derived low pathogenic avian influenza virus subtype H16N3 causes limited infection | |
RU2012119175A (ru) | Способ оценки состояния гиперпролиферативных заболеваний шейки матки | |
Knuuttila | Diagnostics and epidemiology of Aleutian mink disease virus | |
CN108754030A (zh) | 一种人ki多瘤病毒的荧光定量pcr引物和探针及其应用 | |
Gameiro et al. | Human Papillomavirus-Associated Tumor Extracellular Vesicles in HPV+ Tumor Microenvironments |